12:00 AM
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Quizartinib: Preliminary Phase IIb data

Preliminary data from an open-label, international Phase IIb trial in 76 patients with relapsed or refractory FLT3-ITD-positive AML showed that continuous treatment with once-daily 30 and 60 mg oral quizartinib in 28-day cycles each led to a CRc rate, a co-primary endpoint, of 47%. Specifically, low-dose quizartinib led to a CR rate of 5% and a CRi rate of 42% and high-dose quizartinib led to a CR rate of 3%, a CRp rate of 3% and a CRi rate of 42% at a minimum follow-up of 8 weeks. Additionally, rates of grade >=2 QTcF interval prolongation - the other co-primary endpoint...

Read the full 483 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >